Randall E. Kaye's Insider Trades & SAST Disclosures
Randall E. Kaye's most recent trade in Longboard Pharmaceuticals Inc was a trade of 175,946 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 2, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Randall E. Kaye.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Longboard Pharmaceuticals Inc | Randall E. Kaye | Executive Vice President & CMO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 175,946 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | Executive Vice President & CMO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 107,560 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | Executive Vice President & CMO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 96,300 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | Executive Vice President & CMO | 02 Dec 2024 | 30,554 | 0 | - | 60 | 1,833,240 | Common Stock | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | Executive Vice President & CMO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 17,920 | 0 | - | - | Restricted Stock Unit | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | Executive Vice President & CMO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 9,500 | 0 | - | - | Restricted Stock Unit | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2024 | 30,554 | 175,946 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.00 per share. | 19 Nov 2024 | 30,554 | 48,474 | - | 6 | 183,324 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 9,500 | 9,500 | - | - | Retention Restricted Stock Units | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.35 per share. | 15 Oct 2024 | 16,667 | 34,587 | - | 4.3 | 72,501 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 59.03 per share. | 15 Oct 2024 | 16,667 | 17,920 | - | 59.0 | 983,936 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2024 | 16,667 | 96,300 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.35 per share. | 16 Sep 2024 | 16,666 | 34,586 | - | 4.3 | 72,497 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 16,666 | 112,967 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 30.89 per share. | 16 Sep 2024 | 9,366 | 25,220 | - | 30.9 | 289,278 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 31.81 per share. | 16 Sep 2024 | 4,200 | 21,020 | - | 31.8 | 133,622 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 34.04 per share. | 16 Sep 2024 | 1,900 | 17,920 | - | 34.0 | 64,668 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 33.12 per share. | 16 Sep 2024 | 1,200 | 19,820 | - | 33.1 | 39,750 | Common Stock |
| Longboard Pharmaceuticals Inc | Kaye E. Randall | CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 107,560 | 107,560 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | E. Randall Kaye | CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 17,920 | 17,920 | - | 0 | Common Stock | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.35 per share. | 23 Jan 2024 | 16,667 | 34,587 | - | 4.3 | 72,501 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 16,667 | 129,633 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 34.55 per share. | 23 Jan 2024 | 10,476 | 24,111 | - | 34.6 | 361,948 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 35.03 per share. | 23 Jan 2024 | 6,191 | 17,920 | - | 35.0 | 216,856 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Purchase of securities on an exchange or from another person at price $ 24.82 per share. | 23 Jan 2024 | 100 | 100 | - | 24.8 | 2,482 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Sale of securities on an exchange or to another person at price $ 20.87 per share. | 23 Jan 2024 | 100 | 0 | - | 20.9 | 2,087 | Common Stock |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 146,300 | 146,300 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Randall E. Kaye | CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 206,500 | 206,500 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges